BioSpace News Archive

In a first-in-human, prospective, randomized, single-blind controlled study of 67 patients, SB-030 demonstrated a positive safety profile, with no clinically meaningful difference observed in adverse events between treatment and control groups.

University of Oxford and Sound Pharma, are pleased to announce the initiation of a Phase II clinical trial of SPI-1005 for the treatment of patients with bipolar disorder.

The in vitro work, carried out by researchers at Southern Research Institute showed that BIOC51 was bactericidal against the following pathogens, several of which have been categorized as a significant public health threat according to the CDC.

The regulatory review process will be proceeding as expected; PDUFA Date Of April 17, 2018.

FIU researchers search DNA for ways to battle bacteria resistant to antibiotics [01-November-2017] MIAMI, Nov. 1, 2017 /PRNewswire-USNewswire/ -- The National Institutes of Health awarded FIU researchers nearly $2 million study on how targeting bacterial DNA can be used to kill antibiotic-resistant superbugs. If successful, the one-of-a-kind work of Bio

Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss the Company’s financial results following the release.

Management will host a conference call beginning at 5:00 p.m. ET to discuss these results and to answer questions.

The company will host a conference call and live audio webcast on Wednesday, November 8, 2017 at 4:30 p.m. ET.

The Board of Directors of Daxor has voted to re-authorize the company’s share buyback for an amount of up to 300,000 shares for the next 12 months.

The study included 70 patients ranging from 8 to 25 years old.